デフォルト表紙
市場調査レポート
商品コード
966336

後期慢性腎不全治療薬の世界市場:将来予測 (2027年まで)、製品種類別・症状別・流通チャネル別・地域別の分析、新型コロナウイルス感染症 (COVID-19) の影響

Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type ; Indication ; Distribution Channel, and Geography

出版日: | 発行: The Insight Partners | ページ情報: 英文 194 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
後期慢性腎不全治療薬の世界市場:将来予測 (2027年まで)、製品種類別・症状別・流通チャネル別・地域別の分析、新型コロナウイルス感染症 (COVID-19) の影響
出版日: 2020年09月16日
発行: The Insight Partners
ページ情報: 英文 194 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の後期慢性腎不全治療薬の市場規模は、2019年の46億8000万から、2027年までに110億9690万米ドルにまで拡大する、と予想されています。また、2020~2027年のCAGRは11.6%と推計されています。

当レポートでは、世界の後期慢性腎臓病向け治療薬の市場について分析し、市場の基本構造や背景事情 (主な促進・抑制要因など)、市場規模の動向見通し (今後9年間分)、製品種類別・症状別・流通チャネル別・地域別の詳細動向、主要企業のプロファイルと戦略展開状況、昨今の新型コロナウイルス感染症 (COVID-19) に伴う影響、といった情報を取りまとめてお届けいたします。

目次

第1章 イントロダクション

第2章 後期慢性腎不全治療薬市場:分析概要

第3章 分析手法

第4章 後期慢性腎不全治療薬市場:市場環境

  • 概要
  • PEST分析
  • 専門家の見解

第5章 世界の後期慢性腎不全治療薬市場:市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の動向
  • 市場促進・抑制要因の影響度の分析

第6章 後期慢性腎不全治療薬市場:世界市場の分析

  • 市場収益額の予測と分析
  • 市場規模の予測と分析:地域別
  • 主要企業の市場ポジショニング

第7章 後期慢性腎不全治療薬市場:製品種類別の分析

  • 概要
  • 後期慢性腎不全治療薬市場:製品種類別シェア (2019年、2027年)
  • カルシウム受容体作動薬 (カルシミメティクス)
  • ビタミンD
  • カリウム結合剤 (バインダー)
  • カルシウムベースのリン吸着剤
  • その他

第8章 後期慢性腎不全治療薬市場:適応症別の分析

  • 概要
  • 後期慢性腎不全治療薬市場:適応症別シェア (2019年、2027年)
  • 後期慢性腎不全誘発性副甲状腺機能亢進症
  • 後期慢性腎不全誘発性高リン血症
  • 後期慢性腎不全誘発性高カリウム血症

第9章 後期慢性腎不全治療薬市場:流通チャネル別の分析

  • 概要
  • 後期慢性腎不全治療薬市場:流通チャネル別シェア (2019年、2027年)
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第10章 後期慢性腎不全治療薬市場の分析・予測:地域別の分析

  • 北米:後期慢性腎不全治療薬の市場
  • 欧州:後期慢性腎不全治療薬の市場
  • アジア太平洋:後期慢性腎不全治療薬の市場
  • 中東・アフリカ:後期慢性腎不全治療薬の市場
  • 中南米:後期慢性腎不全治療薬の市場

第11章 COVID-19感染拡大が世界の後期慢性腎不全治療薬市場に及ぼす影響

  • 北米:COVID-19感染拡大の影響度の評価
  • 欧州:COVID-19感染拡大の影響度の評価
  • アジア太平洋:COVID-19感染拡大の影響度の評価
  • 他の国々 (RoW):COVID-19感染拡大の影響度の評価

第12章 後期慢性腎不全治療薬の市場:業界情勢

  • 概要
  • 各企業が展開した成長戦略
  • 有機的発展
  • 無機的発展

第13章 企業プロファイル

  • AbbVie Inc.
  • Amgen
  • AstraZeneca
  • Sanofi
  • Kyowa Kirin Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Bayer AG
  • Vifor Pharma Management Ltd.
  • Akebia Therapeutics, Inc.

第14章 付録

図表

List Of Tables

  • Table 1. North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 2. North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 3. North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 4. US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 5. US: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 6. US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 7. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 8. Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 9. Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 10. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 11. Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 12. Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 13. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 14. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 15. Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 16. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 17. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 18. Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 19. France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 20. France: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 21. France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 22. UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 23. UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 24. UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 25. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 26. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 27. Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 28. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 29. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 30. Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 31. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 32. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 33. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 34. China Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 35. China Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 36. China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 37. Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 38. Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 39. Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 40. India Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 41. India Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 42. India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 43. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 44. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 45. South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 46. Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 47. Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 48. Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 49. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
  • Table 50. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
  • Table 51. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 52. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 53. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 54. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 55. UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
  • Table 56. UAE Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 57. UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 58. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 59. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 60. South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel- Revenue and Forecast to 2027(USD Million)
  • Table 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 62. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 63. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel- Revenue and Forecast to 2027(USD Million)
  • Table 64. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 65. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 66. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 67. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
  • Table 68. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
  • Table 69. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • Table 70. Organic Developments Done By Companies
  • Table 71. Inorganic Developments Done by Companies
  • Table 72. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market

List Of Figures

  • Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation
  • Figure 2. Late Stage Chronic Kidney Disease Drugs Market - By Geography
  • Figure 3. Global Late Stage Chronic Kidney Disease Drugs Market Overview
  • Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market
  • Figure 5. Asia-Pacific to Show Remarkable Growth During Forecast Period
  • Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market, By Geography (US$ Million)
  • Figure 7. Global Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)
  • Figure 8. Global Late Stage Chronic Kidney Disease Drugs Market, Industry Landscape
  • Figure 9. North America PEST Analysis
  • Figure 10. Europe PEST Analysis
  • Figure 11. Asia-Pacific PEST Analysis
  • Figure 12. Middle East and Africa (MEA) PEST Analysis
  • Figure 13. South & Central America (SCAM) PEST Analysis
  • Figure 14. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints
  • Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market - Revenue Forecast And Analysis - 2019- 2027
  • Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market - By Geography Forecast and Analysis - 2019- 2027
  • Figure 17. Market Positioning of Key Players
  • Figure 18. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
  • Figure 19. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 20. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 21. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 22. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 23. Others: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 24. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
  • Figure 25. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 26. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 27. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 28. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
  • Figure 29. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 30. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 31. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 32. North America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 33. North America: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 34. North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 35. US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 36. Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 37. Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 38. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 39. Europe: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 40. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 41. Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 42. France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 43. UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 44. Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 45. Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 46. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 47. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 48. Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 49. China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 50. Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 51. India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 52. South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 53. Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 54. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 55. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 56. Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)
  • Figure 57. Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 58. UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 59. South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 60. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 61. South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
  • Figure 62. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
  • Figure 63. Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 64. Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 65. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In North American Countries
  • Figure 66. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In European Countries
  • Figure 67. Impact of COVID-19 Pandemic On Late Stage Chronic Kidney Disease Drugs Market In Asia Pacific Countries
  • Figure 68. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in Rest of the World
  • Figure 69. Growth Strategies Done by the Companies in the Market, (%)
目次
Product Code: TIPRE00013768

Title:
Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography.

The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020-2027.

The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage, the kidney loses its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life.

At present, there is no cure for chronic kidney disease, and treatment involves the managing of the disease. Blood pressure medications, such as angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, are frequently prescribed to control hypertension, and expectantly, to slowdown the progression of chronic kidney disease. Therefore, the manufacturers in the market are focusing on adopting strategies such as product launches and approvals, R&D investments, government funding, and partnerships to develop new drugs and provide easy access for the patients worldwide.

Some of the manufactures are mentioned below:

DiaMedica Drugs

On February 14, 2019 DiaMedica Drugs Inc, a clinical-stage biotechnology company, announced that it has initiated dosing patients with chronic kidney disease in a Phase Ib clinical study evaluating DM199. The course is conducted in the U.S., is a multi-center, open-label clinical trial to assess the tolerability, safety, and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. This study will help determine the dose levels required to restore normal KLK1 protein levels in patients with CKD and provide extra insights about the specific CKD patient populations that may benefit most from DM199 treatment and guide the upcoming design Phase II studies.

Cara Drugs, Inc.

Cara Drugs, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to improve pruritus and pain by selectively targeting peripheral kappa opioid receptors, on July 2017 announced that it had dosed the first patient in its Phase 1 pharmacokinetic and safety trial of Oral CR845 tablets in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis.

Akebia Drugs

Akebia Drugs, Inc., a biopharmaceutical company engaged in the development of the with the purpose to better the lives of people impacted by kidney disease, on June 2020 announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD). Moreover, Mitsubishi Tanabe Pharma Corporation, Akebia's collaboration partner in Japan for vadadustat, has received manufacturing and marketing approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour, and Welfare in Japan. Mitsubishi Tanabe Pharma Corporation will market Vadadustat in Japan under the trade name VAFSEO.

Based on product type, the market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.

Based on indication, the global late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. The late stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), European Federation of Pharmaceutical Industry Associations, Pharmaceutical Research, National Kidney Foundation, and Organization for Economic Cooperation and Development are among the major primary and secondary sources referred for preparing this report.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the late stage chronic kidney disease drugs market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global late stage chronic kidney disease drugs market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Late Stage Chronic Kidney Disease Drugs Market - By Product Type
    • 1.3.2 Late Stage Chronic Kidney Disease Drugs Market - By Indication
    • 1.3.3 Late Stage Chronic Kidney Disease Drugs Market - By Distribution Channel
    • 1.3.4 Late Stage Chronic Kidney Disease Drugs Market - By Geography

2. Late Stage Chronic Kidney Disease Drugs Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Late Stage Chronic Kidney Disease Drugs Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America - PEST Analysis
    • 4.2.2 Europe - PEST Analysis
    • 4.2.3 Asia-Pacific - PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) - PEST Analysis
    • 4.2.5 South & Central America (SCAM) - PEST Analysis
  • 4.3 Expert Opinion

5. Late Stage Chronic Kidney Disease Drugs Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases
    • 5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs
  • 5.2 Market Restraints
    • 5.2.1 Delay in the Diagnosis of Chronic Kidney Disease
  • 5.3 Market Opportunities
    • 5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
  • 5.4 Future Trends
    • 5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
  • 5.5 Impact Analysis

6. Late Stage Chronic Kidney Disease Drugs Market - Global Analysis

  • 6.1 Global Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast And Analysis
  • 6.2 Global Late Stage Chronic Kidney Disease Drugs Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Late Stage Chronic Kidney Disease Drugs Market Analysis - By Product Type

  • 7.1 Overview
  • 7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
  • 7.3 Calcimimetics
    • 7.3.1 Overview
    • 7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.4 Vitamin D
    • 7.4.1 Overview
    • 7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.5 Potassium Binders
    • 7.5.1 Overview
    • 7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.6 Calcium-Based Phosphate Binders
    • 7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.7 Others
    • 7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

8. Late Stage Chronic Kidney Disease Drugs Market Analysis By Indication

  • 8.1 Overview
  • 8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
  • 8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
    • 8.3.1 Overview
    • 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
    • 8.4.1 Overview
    • 8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia
    • 8.5.1 Overview
    • 8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

9. Late Stage Chronic Kidney Disease Drugs Market Analysis By Distribution Channel

  • 9.1 Overview
  • 9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)
  • 9.3 Hospital Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.4 Online Pharmacies
    • 9.4.1 Overview
    • 9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.5 Retail Pharmacies
    • 9.5.1 Overview
    • 9.5.2 Retail Pharmacies Segment : Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

10. Late Stage Chronic Kidney Disease Drugs Market Analysis And Forecasts To 2027 - Geographical Analysis

  • 10.1 North America: Late Stage Chronic Kidney Disease Drugs Market
    • 10.1.1 Overview
    • 10.1.2 North America: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.1.3 North America: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.1.4 North America: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.1.5 North America: Late Stage Chronic Kidney Disease Drugs Market, By Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.6 North America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.1.7 US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.1 US: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.2 US: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.3 US: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.4 US: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.8 Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.1 Canada: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.2 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.3 Canada: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.4 Canada: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.1.9 Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.1 Mexico: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.2 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.3 Mexico: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.4 Mexico: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.2 Europe: Late Stage Chronic Kidney Disease Drugs Market
    • 10.2.1 Overview
    • 10.2.2 Europe: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.2.3 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.2.4 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.2.5 Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.6 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.2.7 Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.1 Germany: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.2 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.3 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.4 Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.8 France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.1 France: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.2 France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.3 France: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.4 France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.9 UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.1 UK: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.2 UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.3 UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.4 UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.10 Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.1 Italy: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.2 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.3 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.4 Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.11 Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.1 Spain: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.2 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.3 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.4 Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.3 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market
    • 10.3.1 Overview
    • 10.3.2 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.3.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.3.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.3.5 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.3.6 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.4.1 China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.1 China: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.2 China Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.3 China Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.1.4 China Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.2 Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.1 Japan: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.2 Japan Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.3 Japan Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.2.4 Japan Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.3 India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.1 India: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.2 India Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.3 India Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.3.4 India Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.4 South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.1 South Korea: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.2 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.3 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.4.4 South Korea Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.4.5 Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.1 Australia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.2 Australia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.3 Australia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.4.5.4 Australia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.5 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market
    • 10.5.1 Overview
    • 10.5.2 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
    • 10.5.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
    • 10.5.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
    • 10.5.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.6 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)
    • 10.5.7 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.1 Saudi Arabia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.2 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.3 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.4 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.8 UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.1 UAE: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.2 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.3 UAE Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.4 UAE Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.5.9 South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.1 South Africa: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.2 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.3 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.4 South Africa Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
  • 10.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market
    • 10.6.1 Overview
    • 10.6.2 South and Central America: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
    • 10.6.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
    • 10.6.4 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
    • 10.6.5 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.6.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
    • 10.6.7 Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.1 Brazil: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.2 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type- Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.3 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication- Revenue and Forecast to 2027 (USD Million)
      • 10.6.7.4 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)
    • 10.6.8 Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.1 Argentina: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.2 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.3 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication - Revenue and Forecast to 2027 (USD Million)
      • 10.6.8.4 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel - Revenue and Forecast to 2027(USD Million)

11. Impact of COVID-19 Pandemic on Global Late Stage Chronic Kidney Disease Drugs Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Late Stage Chronic Kidney Disease Drugs Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 AbbVie Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Amgen
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 AstraZeneca
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Sanofi
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Kyowa Kirin Co., Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Takeda Pharmaceutical Company Limited
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Astellas Pharma Inc.
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bayer AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Vifor Pharma Management Ltd.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Akebia Therapeutics, Inc.
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 Glossary of Terms